Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Acute lymphoblastic leukemia (ALL) Clinical Trials

Protocol Number Title
2007NT102
COG AALL05B1: A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Samples.
2009NTLS130
Hematologic Malignancy Tissue Bank Formerly: "Leukemia, Lymphoma and MDS Tissue Bank" Formerly: "Leukemia and MDS Tissue Bank" & "Pediatric Leukemia Tissue Bank"
2010NTCG113
COG AALL08B1 - Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
2011CG161
COG AALL1131 - A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations. Additional Title: Per Case Reimbursement NIH National Clinical Trials Network (NCTN) BIQSFP Grant U10CA180886-02S7 Add: AALL1131 Osteonecrosis Sub-study Per Case Reimbursement
2012CG099
COG ACCL1033 - A Comprehensive Approach to Improving Medication Compliance in Pediatric ALL
2014CG089
COG AALL1231 - A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
2014CG123
MT2016-21 : COG AALL1331 - Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) "AALL1331 - Amgen, Inc."
2014IS068
HM2015-05R : Novartis CCTL019B2206: A Multicenter study of apheresis collection of peripheral blood mononuclear cells (PBMC) in patients with CD19 expressing malignancies who could be eligible for a CTL019 clinical research trial
2015NTIS003
MT2015-16R:Novartis CCTL019A2205B; MT2015-16R: Long Term Follow-Up of Patients Exposed to Lentiviral- Based CD19 directed CART Cell Therapy

9 trials displayed